TerminatedPhase 2NCT05634577

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Studying Adrenocortical carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Mouhammed Habra, MD
M.D. Anderson Cancer Center
Intervention
Mitotane(drug)
Enrollment
3 enrolled
Eligibility
18 years · All sexes
Timeline
20232024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05634577 on ClinicalTrials.gov

Other trials for Adrenocortical carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adrenocortical carcinoma

← Back to all trials